

# Erik Thunnissen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/170142/erik-thunnissen-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126  
papers

13,604  
citations

47  
h-index

116  
g-index

129  
ext. papers

16,680  
ext. citations

5.7  
avg, IF

5.6  
L-index

#	Paper	IF	Citations
126	Diagnosis of atypical carcinoid can be made on biopsies > 4 mm and is accurate.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2022</b> , 480, 587	5.1	
125	The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.. <i>Lung Cancer</i> , <b>2022</b> , 166, 143-149	5.9	0
124	Influence of preanalytical variables on performance of delta-like protein 3 (DLL3) predictive immunohistochemistry. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 478, 293-300	5.1	1
123	The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. <i>Lung Cancer</i> , <b>2021</b> , 154, 161-175	5.9	24
122	RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 798-806	8.9	9
121	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 990-1002	8.9	6
120	COVID-19: Histopathological correlates of imaging patterns on chest computed tomography. <i>Respirology</i> , <b>2021</b> , 26, 869-877	3.6	3
119	Polarization-sensitive optical coherence tomography in end-stage lung diseases: an ex vivo pilot study. <i>Biomedical Optics Express</i> , <b>2021</b> , 12, 6796-6813	3.5	1
118	Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non-Small-Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 1438-1452	5.1	2
117	Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples. <i>BMC Cancer</i> , <b>2020</b> , 20, 366	4.8	2
116	Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 392-402	8.7	11
115	Tumor Atelectasis Gives Rise to a Solid Appearance in Pulmonary Adenocarcinomas on High-Resolution Computed Tomography. <i>JTO Clinical and Research Reports</i> , <b>2020</b> , 1, 100018	1.4	
114	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1409-1424	8.9	80
113	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1599-1610	8.9	52
112	Quantification of PD-L1 Expression with F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1455-1460	8.9	25
111	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 709-740	8.9	77
110	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 499-519	8.9	99

109	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , <b>2020</b> , 33, 792-801	9.8	18
108	External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. <i>Journal of Pathology: Clinical Research</i> , <b>2020</b> , 6, 138-145	5.3	12
107	Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 423-430	3.9	7
106	Morphologic Logic: "Filigree" and "Classical" Micropapillary Pattern Are Orientation-Dependent Views of the Same Lesion. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, e120-e121	8.9	1
105	Lung cancer biomarker testing: perspective from Europe. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 887-897	4.4	8
104	RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, e116-e117	8.9	1
103	Pathologists should probably forget about kappa. Percent agreement, diagnostic specificity and related metrics provide more clinically applicable measures of interobserver variability. <i>Annals of Diagnostic Pathology</i> , <b>2020</b> , 47, 151561	2.2	4
102	Correlation of ROS1 Immunohistochemistry With Fusion Status Determined by Fluorescence In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2020</b> , 144, 735-741	5	13
101	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , <b>2019</b> , 131, 95-103	5.9	22
100	Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, S37-S44	2.6	11
99	A Population-Based Study of Outcomes in Surgically Resected T3N0 Non-Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging Algorithm. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 459-467	8.9	6
98	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 377-407	8.9	114
97	Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. <i>Journal of Proteomics</i> , <b>2019</b> , 196, 106-119	3.9	11
96	In Reply. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2019</b> , 143, 909-910	5	1
95	Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2019</b> , 475, 191-199	5.1	23
94	Clonality analysis of pulmonary tumors by genome-wide copy number profiling. <i>PLoS ONE</i> , <b>2019</b> , 14, e0223827	3.7	5
93	Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens?. <i>Histopathology</i> , <b>2019</b> , 74, 555-566	7.3	23
92	PD-L1 Antibody Comparison in Urothelial Carcinoma. <i>European Urology</i> , <b>2019</b> , 75, 538-540	10.2	26

91	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 222-259	8.9	241
90	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 222-259	5	371
89	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 129-159	5.1	165
88	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 205-217	8.9	22
87	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 413-425	8.9	48
86	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1337-1343	12.9	44
85	Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1222-1226	8.9	40
84	Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 253-262	5	79
83	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 408-419	5	52
82	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1569-1576	8.9	140
81	New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1410-1414	8.9	23
80	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1302-1311	8.9	381
79	Pulmonary loose tumor tissue fragments and spread through air spaces (STAS): Invasive pattern or artifact? A critical review. <i>Lung Cancer</i> , <b>2018</b> , 123, 107-111	5.9	20
78	Comprehensive Hybrid Capture-Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative by FISH. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, e22-e24	8.9	7
77	DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2 years. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 250-254	3.9	15
76	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 334-346	8.9	67
75	PD-L1 IHC in NSCLC with a global and methodological perspective. <i>Lung Cancer</i> , <b>2017</b> , 113, 102-105	5.9	25
74	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope project. <i>Lung Cancer</i> , <b>2017</b> , 111, 143-149	5.9	31

73	Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases.". <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, e70-e71	8.9	2
72	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmler and Alberto Cavazza. <i>European Respiratory Review</i> , <b>2017</b> , 26,	9.8	49
71	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2017</b> , 470, 5-20	5.1	62
70	Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9042-9042	2.3	7
69	Genetic subtypes of large cell neuroendocrine carcinoma (LCNEC) to predict response to chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9061-9061	2.2	6
68	Whole body PD-1 and PD-L1 PET with 89Zr-nivolumab and 18F- BMS-986192 in pts with NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20047-e20047	2.2	7
67	Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8516-8516	2.2	
66	ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment Regimen. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 2241-2247	8.9	32
65	Testing for ROS1 in non-small cell lung cancer: a review with recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2016</b> , 469, 489-503	5.1	146
64	Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?. <i>Familial Cancer</i> , <b>2016</b> , 15, 297-300	3	1
63	Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC. <i>EJNMMI Research</i> , <b>2016</b> , 6, 10	3.6	17
62	A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 593-602	8.9	9
61	Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. <i>Thorax</i> , <b>2016</b> , 71, 177-84	7.3	114
60	Clinical features of large cell neuroendocrine carcinoma: a population-based overview. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 615-24	13.6	66
59	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 1066-75	3.3	120
58	Ex Vivo Artifacts and Histopathologic Pitfalls in the Lung. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2016</b> , 140, 212-20	5	55
57	Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. <i>Lung Cancer</i> , <b>2015</b> , 89, 255-61	5.9	66
56	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , <b>2015</b> , 524, 47-53	50.4	1061

55	Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. <i>Journal of Clinical Pathology</i> , <b>2015</b> , 68, 320-1	3.9	29
54	Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial Lesions. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 1483-9	10.2	24
53	Diagnostic challenges in survivors of early stage lung cancer. <i>Lung Cancer</i> , <b>2015</b> , 90, 212-6	5.9	3
52	Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 765-73	13.6	65
51	Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy. <i>Personalized Medicine</i> , <b>2015</b> , 12, 63-66	2.2	1
50	Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?. <i>Lung Cancer</i> , <b>2015</b> , 89, 19-26	5.9	7
49	Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. <i>Cellular Oncology (Dordrecht)</i> , <b>2014</b> , 37, 353-61	7.2	38
48	Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1342-50	21.7	201
47	The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. <i>PLoS ONE</i> , <b>2014</b> , 9, e112159	3.7	24
46	Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis. <i>Journal of Clinical Pathology</i> , <b>2014</b> , 67, 707-11	3.9	41
45	Guidance for laboratories performing molecular pathology for cancer patients. <i>Journal of Clinical Pathology</i> , <b>2014</b> , 67, 923-31	3.9	128
44	Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2780-7	2.2	136
43	Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1354-62	8.9	31
42	Prognostic and predictive biomarkers in lung cancer. A review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 464, 347-58	5.1	65
41	Sorafenib and metformin in pretreated patients with stage IV non-small cell lung cancer with a KRAS mutation: A multicenter single arm phase II study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19015-e19015 <sup>2</sup>	5.1	23
40	Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2013</b> , 462, 547-56	5.1	11
39	Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2013</b> , 462, 27-37	5.1	59
38	EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study. <i>Lung Cancer</i> , <b>2013</b> , 82, 38-43	5.9	24

37	Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 848-54	10.2	142
36	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , <b>2013</b> , 15, 145-53	5.1	340
35	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2013</b> , 137, 828-60	5	365
34	A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation. <i>Familial Cancer</i> , <b>2013</b> , 12, 373-9	3	15
33	Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. <i>European Respiratory Journal</i> , <b>2013</b> , 42, 1659-67	13.6	143
32	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 668-73	8.9	632
31	Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2013</b> , 137, 668-84	5	287
30	Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2013</b> , 137, 1255-61	5	23
29	Tumor size does not predict pathological complete response rates after pre-operative chemoradiotherapy for non-small cell lung cancer. <i>Acta Oncologica</i> , <b>2013</b> , 52, 676-8	3.2	2
28	In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2013</b> , 137, 1792-7	5	12
27	Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2013</b> , 137, 685-705	5	117
26	CD44 and OTP are strong prognostic markers for pulmonary carcinoids. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2197-207	12.9	57
25	A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 743-51	12.9	61
24	Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 183-93	12.9	90
23	KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1190-5	8.9	27
22	The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 11085-11085	2.2	1
21	Rebiopsy in TKI-resistance: A retrospective analysis.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8065-8065	2.2	0
20	Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3Pdeoxy-3P[ <sup>18</sup> F]fluorothymidine positron emission tomography. <i>PLoS ONE</i> , <b>2013</b> , 8, e63705	3.7	17

19	KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. <i>Journal of Molecular Diagnostics</i> , <b>2012</b> , 14, 247-55	5.1	47
18	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. <i>Modern Pathology</i> , <b>2012</b> , 25, 1574-83	9.8	155
17	EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2012</b> , 461, 245-57	5.1	168
16	Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2012</b> , 461, 629-38	5.1	27
15	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , <b>2012</b> , 44, 1104-10	36.3	919
14	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. <i>Lung Cancer</i> , <b>2012</b> , 76, 1-18	5.9	171
13	Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 541-5	3.9	18
12	An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary?. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, e3-5	8.9	2
11	Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1522-7	8.9	19
10	Applying biomarker testing to clinical practice in lung cancer. <i>Lung Cancer Management</i> , <b>2012</b> , 1, 145-154	4.6	
9	Successful treatment of diffuse pulmonary lymphangiomatosis with bevacizumab. <i>Annals of Internal Medicine</i> , <b>2012</b> , 156, 839-40	8	24
8	Pulmonary adenocarcinoma histology. <i>Translational Lung Cancer Research</i> , <b>2012</b> , 1, 276-9	4.4	3
7	Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2581-90	12.9	78
6	EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. <i>Journal of Clinical Pathology</i> , <b>2011</b> , 64, 884-92	3.9	28
5	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 244-85	8.9	3178
4	Bronchioloalveolar adenocarcinoma and pulmonary langerhans cell histiocytosis in a patient with MUTYH-associated polyposis. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e188-90	2.2	2
3	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 62ra93	17.5	646
2	Management of lung nodules detected by volume CT scanning. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2221-9	59.2	598



- 1 Epidemiological and clinical aspects of lung cancer 945-1003